RxDoctor Payments Data

Eric Meissner, MD

Infectious Disease · Charleston, SCNPI 1497954036

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (37.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 3 manufacturers reported payments, led by Theratechnologies Inc. at 37.2% of the total.

$4,029in general payments, 2019–2025

Across 15 payments — averaging $268.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Theratechnologies Inc.$2K
  • Viiv Healthcare Company$1K
  • Merck$1K
$1,622,342in research payments, 2019–2025

Across 125 payments — averaging $12,979 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Viiv Healthcare Company$924K
  • Regeneron$522K
  • Gilead$157K
  • Theratechnologies Inc.$20K

What the payments were for

  • Consulting fees$1,17429%
  • Speaking & faculty fees$1,50037%
  • Travel & lodging$88922%
  • Food & beverage$46612%

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Theratechnologies Inc.1$1,500
Viiv Healthcare Company5$1,299
Merck9$1,230

How this compares

$4,029 in reported general payments places this provider in the 80th percentile of 102 infectious disease providers in South Carolina.

See all infectious disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$7,877
Medicare patients
51
Services billed
108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala431$1,681,913
DovatoDolutegravir Sodium/Lamivudine103$300,520
TivicayDolutegravir Sodium67$200,182
GenvoyaElviteg/Cob/Emtri/Tenof Alafen33$128,447
CabenuvaCabotegravir/Rilpivirine19$120,632
TriumeqAbacavir/Dolutegravir/Lamivudi28$107,292
OdefseyEmtricitab/Rilpiviri/Tenof Ala27$97,179
DescovyEmtricitabine/Tenofov Alafenam38$79,893
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf14$63,771
PifeltroDoravirine33$56,057
Darunavir39$39,243
EdurantRilpivirine Hcl26$37,693
PrezcobixDarunavir/Cobicistat14$32,810
Etravirine12$14,145
TrulicityDulaglutide12$11,029

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyDovato, Tivicay, Cabenuva, Triumeq$1,299$728,626217 claims
MerckPifeltro$1,230$56,05733 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 102 infectious disease providers in South Carolina.

Other infectious disease in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →